Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China flag China · Delayed Price · Currency is CNY
32.65
+0.21 (0.65%)
May 12, 2026, 3:00 PM CST

SHA:688076 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
783.96913.79571.39749.08399.96591.88
Trading Asset Securities
156.9116208-43.0187.13
Cash & Short-Term Investments
940.861,030779.39749.08442.98679.01
Cash Growth
28.07%32.13%4.05%69.10%-34.76%353.54%
Accounts Receivable
537.8508.32539.21297.26251.29143.37
Other Receivables
7.727.67.923.271.191.05
Receivables
545.53515.92547.13300.53252.48144.41
Inventory
899.34859.52584.04377.17323.48250.82
Other Current Assets
101.51107.1694.9767.9833.5329.86
Total Current Assets
2,4872,5122,0061,4951,0521,104
Property, Plant & Equipment
3,0392,9921,8921,405988.47706.55
Long-Term Investments
73.29234.47215.04117.594.5-
Goodwill
156.34156.34156.34156.34156.34160.92
Other Intangible Assets
204.41154.82108.19112.198.1888.57
Long-Term Deferred Tax Assets
131.02128.2188.2746.6528.1316.63
Long-Term Deferred Charges
310.22347.59203.241.0338.7715.66
Other Long-Term Assets
413.94214.69409.4173.8465.4434.46
Total Assets
6,8166,7405,0783,5472,5222,127
Accounts Payable
609.37667.84159.7141.9387.6172.36
Accrued Expenses
78.5296.39149.1286.1448.4943.99
Short-Term Debt
1,0221,0171,044546.02318.7377.27
Current Portion of Long-Term Debt
-291.4117.8940.08--
Current Portion of Leases
--9.795.291.473.64
Current Income Taxes Payable
-1219.3511.475.37-
Current Unearned Revenue
42.6948.1761.218.396.8526.17
Other Current Liabilities
373.7130.24191.83134.0182.851.96
Total Current Liabilities
2,1272,1631,753973.34551.32275.4
Long-Term Debt
1,3221,322445.21286.49--
Long-Term Leases
27.4428.8925.7517.18-2.74
Long-Term Unearned Revenue
154.79156.855.9931.4635.3221.74
Long-Term Deferred Tax Liabilities
7.78.278.6110.1610.774.26
Other Long-Term Liabilities
48.3259.18107.4339.31-14
Total Liabilities
3,6863,7392,3961,358597.41318.14
Common Stock
316.05316.05219.78213.18213.18213.18
Additional Paid-In Capital
1,7551,7551,5981,3411,3191,318
Retained Earnings
1,049919.08792.51495.37374.95277.82
Comprehensive Income & Other
-4.11-4.3650.11120.233.332.2
Total Common Equity
3,1162,9862,6602,1701,9101,811
Minority Interest
13.6416.221.9519.0414.66-2.61
Shareholders' Equity
3,1293,0022,6822,1891,9251,809
Total Liabilities & Equity
6,8166,7405,0783,5472,5222,127
Total Debt
2,3712,6601,642895.07320.1983.65
Net Cash (Debt)
-1,430-1,630-863.06-145.98122.79595.36
Net Cash Growth
-----79.38%-
Net Cash Per Share
-4.52-5.20-2.81-0.490.412.21
Filing Date Shares Outstanding
315.76316.05307.69298.46298.46298.46
Total Common Shares Outstanding
315.76316.05307.69298.46298.46298.46
Working Capital
360.63349.12252.82521.43501.15828.71
Book Value Per Share
9.879.458.657.276.406.07
Tangible Book Value
2,7552,6742,3961,9021,6561,562
Tangible Book Value Per Share
8.738.467.796.375.555.23
Buildings
--516.19504.29476.24376.08
Machinery
--1,6031,123652.13529
Construction In Progress
--339.92185.96180.1134.85
Source: S&P Global Market Intelligence. Standard template. Financial Sources.